Courtesy: Pacom
Canada, which has been slow to respond to a changing trans-Pacific neighbourhood, can join India and the ASEAN member states to embark on a trilateral dialogue on the Indo-Pacific’s importance in terms of political, strategic and other domains. An alignment in outlook can strengthen the security and prosperity of a region, currently mired in U.S.-China rivalries
Courtesy: NTNU
The emergence of the Fourth Industrial Revolution depends on the availability of rare- earth minerals, which occur extensively on the ocean floor of the Indo-Pacific. The technology to exploit this is available only to some countries currently: the global agreement on this must be fair and safeguard India’s future interests, says the author of this blog
Courtesy: Pixabay/Comfreak
The two countries’ proposal to carry out a robotic sample-return mission to the Moon in the 2020s is a laudable attempt at catching up with Beijing’s rather more advanced lunar agenda. And there are many lessons that Japan can offer India
Courtesy: ustr.gov
The Trans-Pacific Partnership has dropped strong Intellectual Property Rights regulations on India’s doorstep. The implications of these regulations could affect India’s own policies, as well as her global aspirations towards the potential Regional Comprehensive Economic Partnership.
Courtesy: NASA's Marshall Space Flight Center/Flickr
An increase in the global demand for rare earth elements, used in high-technology industries, coupled with limited supplies on Earth, has accelerated extra-terrestrial exploration. International cooperation and competition for these space-based resources will determine the next human footprint and race in space.
The annual India-Japan Prime Ministers’ summit, held recently in Tokyo, charted the path for increased Japanese assistance in India’s infrastructural arena. Gateway House interviews Soichi Yamamoto on the potential of this bilateral engagement
This daily column includes Gateway House’s Badi Soch – big thought – of the day’s foreign policy events. Today’s focus is on the $500 million fine levied on Ranbaxy by the U.S. Food and Drug Administration.
